Comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells".
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 23740897.
- Also identified by DOI 10.1126/scitranslmed.3005065 and PMC identifier 3936961.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Egawa et al. recently showed the value of patient-specific induced pluripotent stem cells (iPSCs) for modeling amyotrophic lateral sclerosis in vitro. Their study and our work highlight the need for complementary assays to detect small, but potentially important, phenotypic differences between control iPSC lines and those carrying disease mutations.
Medical subject headings
- Amyotrophic Lateral Sclerosis
- Drug Evaluation, Preclinical
- Induced Pluripotent Stem Cells
- Motor Neurons